AstraZeneca Reports Positive Results From Phase III Trial With Datopotamab Deruxtecan

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said high-level results from the TROPION-Breast01 Phase III trial with datopotamab deruxtecan showed a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. The company said the data will be presented at a forthcoming medical meeting and shared with health authorities.

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate being jointly developed by AstraZeneca and Daiichi Sankyo. The companies have two additional Phase III trials evaluating datopotamab deruxtecan in breast cancer.

For More Such Health News, visit rttnews.com.